GOVX

GeoVax Labs, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000832489 Biotech & Drug Discovery

$0.2066 +0.01 (+6.49%)

Oct 27 4:00 PM ET · prev $0.1940

Market cap

$2.1M

Nano cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

$10.00

+4740% · range $10.00–10.00

Next earnings

Nov 11

in 15 days · EPS est. −$1.09

1 year

−98.6%

from $14.32 · Oct 27

30 days

−40.3%

from $0.3460

52-week range

$0.1940–14.98

−99% from high · low Oct 26

Avg volume 20D

905.1K

Oct 5 spike 11.58M

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Reddit crowd

50°

Neutral · 1 mention this week

SecBot read BEARISH 2 reports · 90 days

Balance 2 bearish · 0 bullish oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 11, 2026

Strongest BEARISH GeoVax Labs' S-1 registration statement (File No. 333-298989) became effective on September 23, 2026…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R May 19 GeoVax Labs entered into a securities purchase agreement to sell com…
X Jul 31 Short interest falls 61.9% to 57.3K
X Aug 14 Short interest jumps 218.4% to 182.4K
X Aug 31 Short interest jumps 101.6% to 367.6K
X Sep 15 Short interest jumps 35.7% to 498.7K
R Sep 24 GeoVax Labs' S-1 registration statement (File No. 333-298989) became…
X Sep 30 Short interest falls 43.5% to 281.8K
E Oct 26 Trial readout: T-90d Trial Readout: COVID-19 Vaccine (Phase 2)

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsMIXED

Q2 2026: 1 added (0 new), 2 trimmed or exited.
AnalystsBULLISH

7 of 8 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$2.120 → −$1.090 over 90 days. 0 up, 1 down in 30 days.
TrendDOWNTREND

49% below its 50-day average. New closing low $0.1940 on Oct 26.
SocialQUIET

Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
GEODE CAPITAL MANAGEMENT, LLC	TRIM	21,112	$26.8K
MORGAN STANLEY	DOUBLED	2,003	$2.5K
UBS Group AG	NEAR_EXIT	944	$1.2K
UBS Group AG	ADD	89,501	$15.3K
NORTHERN TRUST CORP	DOUBLED	64,711	$11.1K
MONETA GROUP INVESTMENT ADVISORS LLC	NEAR_EXIT	800	$3.4K
BANK OF AMERICA CORP /DE/	TRIM	264	$45.00
MORGAN STANLEY	NEAR_EXIT	120	$21.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy2Buy5Hold1Sell0Strong Sell0

12-month targets · 2 analysts

$0.2066 $10.00 $10.00 $10.00

Price is below the lowest target. Median implies +4740%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 15, 2026	Noble Capital Markets MAINTAIN	MAINTAIN	Outperform

Crowd this week 50° Neutral 0 bullish · 0 bearish

Mentions, 7 days 1 0 in posts · 1 in comments

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Jun 17, 2026	MCNALLY ROBERT T Director	AWARD	6,000 sh
Jun 17, 2026	Morgan Jayne Director	AWARD	6,000 sh
Jun 17, 2026	SPENCER JOHN N JR Director	AWARD	6,000 sh
Jun 17, 2026	Reynolds Mark CFO	AWARD	17,600 sh
Jun 17, 2026	McKee Kelly T. Jr. Chief Medical Officer	AWARD	17,600 sh
Jun 17, 2026	DODD DAVID A President, CEO	AWARD	29,300 sh
Jun 17, 2026	NEWMAN MARK J Chief Scientific Officer	AWARD	17,600 sh
Jun 17, 2026	Lemerond Nicole Director	AWARD	6,000 sh

Earnings setup

Estimates

Nov 11

reports in 15 days

−$1.09

EPS estimate, this quarter

+49%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$2.120

90d

−$2.120

60d

−$1.090

30d

−$1.090

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$1.09	-$1.09–-$1.09	+0.0%	$0.00
Next Q	-$1.20	-$1.20–-$1.20	+0.0%	$0.00
Current FY	-$5.14	-$5.14–-$5.14	+0.0%	$0.00
Next FY	-$2.85	-$3.07–-$2.64	+0.0%	$0.00